Concurrent prescriptions for opioids and benzodiazepines and risk of opioid overdose: protocol for a retrospective cohort study using linked administrative data

被引:7
|
作者
Liu, Erin Y. [1 ,2 ]
Tamblyn, Robyn [1 ,2 ,3 ]
Filion, Kristian B. [1 ,3 ,4 ]
Buckeridge, David L. [1 ,2 ,3 ]
机构
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, McGill Clin & Hlth Informat, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
[4] Jewish Gen Hosp, Ctr Clin Epidemiol, Lady Davis Inst, Montreal, PQ, Canada
来源
BMJ OPEN | 2021年 / 11卷 / 02期
关键词
epidemiology; adverse events; public health; UNITED-STATES; MEDICATION USE; DRUG; PREVALENCE; EXPOSURE; THERAPY; ALCOHOL; DEATHS; BIAS;
D O I
10.1136/bmjopen-2020-042299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Opioid overdoses have increased substantially over the last 20 years, with over 400 000 deaths in North America. While opioid prescribing has been a target of research, benzodiazepine and opioid co-intoxication has emerged as a potential risk factor. Our aim was to assess the risk of opioid overdose associated with concurrent use of opioids and benzodiazepines relative to opioids alone. Methods and analysis A retrospective cohort study will be conducted using medical claims data from adult residents of Montreal, Canada. We will create a cohort of new users of opioids (ie, no opioid dispensations in prior year) in 2000-2014 from people with at least 2 years of continuous health insurance. Those with any diagnosis or hospitalisation for cancer or palliative care in the 2 years before their first opioid dispensation will be excluded. On each person-day of follow-up, exposure status will be classified into one of four mutually exclusive categories: (1) opioid-only, (2) benzodiazepine-only, (3) both opioid and benzodiazepine (concurrent use) or (4) neither. Opioid overdose will be measured using diagnostic codes documented in the hospital discharge abstract database, physician billing claims from emergency department visits and death records. Using a marginal structural Cox proportional hazards model, we will compare the hazard of overdose during intervals of concurrent opioid and benzodiazepine use to intervals of opioid use alone, adjusted for sociodemographics, medical and psychiatric comorbidities, and substance use disorders. Ethics and dissemination This study is approved by the McGill Faculty of Medicine Institutional Review Board and the Commission d'access a l'information (Quebec privacy commission). Results will be relevant to clinicians, policymakers and other researchers interested in co-prescribing practices of opioids and benzodiazepines. Study findings will be disseminated at relevant conferences and published in biomedical and epidemiological peer-reviewed journals.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data
    Hartung, Daniel M.
    McCracken, Caitlin M.
    Nguyen, Thuan
    Kempany, Katherine
    Waddell, Elizabeth Needham
    [J]. JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2023, 147
  • [2] CONCOMITANT USE OF OPIOID AND BENZODIAZEPINES AND THE RISK OF OPIOID OVERDOSE REQUIRING HOSPITALIZATIONS: A RETROSPECTIVE COHORT STUDY
    Dave, C.
    Alrwisan, A.
    Zhu, Y.
    Winterstein, A.
    Hartzema, A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A212 - A212
  • [3] Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
    Heather Palis
    Chloé Xavier
    Sabina Dobrer
    Roshni Desai
    Kali-olt Sedgemore
    Marnie Scow
    Kurt Lock
    Wenqi Gan
    Amanda Slaunwhite
    [J]. BMC Public Health, 22
  • [4] Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
    Palis, Heather
    Xavier, Chloe
    Dobrer, Sabina
    Desai, Roshni
    Sedgemore, Kali-olt
    Scow, Marnie
    Lock, Kurt
    Gan, Wenqi
    Slaunwhite, Amanda
    [J]. BMC PUBLIC HEALTH, 2022, 22 (01)
  • [5] Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
    Brat, Gabriel A.
    Agniel, Denis
    Beam, Andrew
    Yorkgitis, Brian
    Bicket, Mark
    Homer, Mark
    Fox, Kathe P.
    Knecht, Daniel B.
    McMahill-Walraven, Cheryl N.
    Palmer, Nathan
    Kohane, Isaac
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [6] ASSESSING THE RISK OF OPIOID OVERDOSE AFTER OPIOID TAPER: A RETROSPECTIVE COHORT STUDY
    Perez, Hector R.
    Gosen, Matthew
    Buonora, Michele
    Cunningham, Chinazo
    Starrels, Joanna L.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S30 - S30
  • [7] Risk of Overdose with Exposure to Prescription Opioids, Benzodiazepines, and Non-benzodiazepine Sedative-Hypnotics in Adults: a Retrospective Cohort Study
    Joanne Cho
    Michele M. Spence
    Fang Niu
    Rita L. Hui
    Patricia Gray
    Steven Steinberg
    [J]. Journal of General Internal Medicine, 2020, 35 : 696 - 703
  • [8] Risk of Overdose with Exposure to Prescription Opioids, Benzodiazepines, and Non-benzodiazepine Sedative-Hypnotics in Adults: a Retrospective Cohort Study
    Cho, Joanne
    Spence, Michele M.
    Niu, Fang
    Hui, Rita L.
    Gray, Patricia
    Steinberg, Steven
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (03) : 696 - 703
  • [9] The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: A retrospective population-based cohort study
    Gisev, Natasa
    Buizen, Luke
    Bharat, Chrianna
    Larney, Sarah
    Currow, David
    Blyth, Fiona M.
    Dobbins, Timothy
    Pearson, Sallie-Anne
    Degenhardt, Louisa
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 589 - 590
  • [10] Prescription opioid use and concurrent psychotropic drug use during pregnancy: A population-based retrospective cohort study utilizing linked administrative data
    Chateau, Dan
    Singal, Deepa
    Hanlon-Dearman, Ana
    Ruth, Chelsea
    Katz, Laurence
    Brownell, Marni
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 181 - 181